Rasburicase (Fasturtec) Registration Trial

Inclusion Criteria: * At high risk of malignancy and/or chemotherapy-induced hyperuricemia * Performance status less than 3 on ECOG scale or more than 30% KPS scale * Uric acid concentrations ≥ 8.0mg/dL * Suffering from non-Hodgkin's lymphoma Stage more than III, or acute lymphoblastic leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma or leukemia Exclusion Criteria: * Treatment with an investigational drug at any time during the 14-day study period (except for agents that are permitted by the Sponsor) * Pregnancy or lactation * Prior treatment with Uricozyme or Rasburicase * Scheduled to receive asparaginase either 24 hours after the first dose of rasburicase * Treatment with Allopurinol within the seven days preceding study Day 1 * History of significant atopic allergy problems or documented history of asthma * History of severe reaction to allopurinol * Known history of glucose-6-phosphate dehydrogenase deficiency. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.